Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

137.95USD
2:50pm GMT
Change (% chg)

$-0.39 (-0.28%)
Prev Close
$138.34
Open
$138.30
Day's High
$138.37
Day's Low
$137.75
Volume
153,526
Avg. Vol
1,708,068
52-wk High
$144.34
52-wk Low
$109.32

Select another date:

Tue, Nov 21 2017

Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study

Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

UPDATE 2-J&J drug succeeds in newly diagnosed multiple myeloma patients-study

Nov 21 Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

J&J multiple myeloma drug succeeds in first-line combination study

Nov 21 Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Johnson & Johnson hit with $247 million verdict in hip implant trial

NEW YORK A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer

A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

UPDATE 3-J&J wins California lawsuit claiming asbestos in talc caused cancer

Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

UPDATE 2-Johnson & Johnson hit with $247 mln verdict in hip implant trial

NEW YORK, Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

J&J wins Calif. lawsuit claiming asbestos in talc caused cancer

Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Johnson & Johnson hit with $247 mln verdict in hip implant trial

NEW YORK, Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation

* Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics

Select another date: